Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.) Patents (Class 424/133.1)
  • Patent number: 10112995
    Abstract: Provided are novel IFB-a binding molecules of human origin, particularly human-derived anti-IFN-? antibodies as well as IFN-? binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits, and methods for use in diagnosis and therapy are described.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: October 30, 2018
    Assignee: ImmunoQure AG
    Inventors: Syeda F. Y. Haque, Adrian Hayday, Kai Kisand, Kai Krohn, Annalisa Macagno, Steffen Meyer, Paert Peterson, Mike Rothe, Philip Vlaicu, Martin Woodward
  • Patent number: 10112988
    Abstract: Blood-brain barrier permeable peptide compositions that contain variable antigen binding domains from camelid and/or shark heavy-chain only single-domain antibodies are described. The variable antigen binding domains of the peptide compositions bind to therapeutic and diagnostic biomarkers in the central nervous system, such as the amyloid-beta peptide biomarker for Alzheimer's disease. The peptide compositions contain constant domains from human IgG, camelid IgG, and/or shark IgNAR. The peptide compositions include heavy-chain only single-domain antibodies and compositions with one or more variable antigen binding domain bound to one or more constant domains.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: October 30, 2018
    Assignee: ICB INTERNATIONAL, INC.
    Inventors: Ram S. Bhatt, Rishi Bhatt
  • Patent number: 10112987
    Abstract: Blood-brain barrier permeable peptide compositions that contain variable antigen binding domains from camelid and/or shark heavy-chain only single-domain antibodies are described. The variable antigen binding domains of the peptide compositions bind to therapeutic and diagnostic biomarkers in the central nervous system, such as the amyloid-beta peptide biomarker for Alzheimer's disease. The peptide compositions contain constant domains from human IgG, camelid IgG, and/or shark IgNAR. The peptide compositions include heavy-chain only single-domain antibodies and compositions with one or more variable antigen binding domain bound to one or more constant domains.
    Type: Grant
    Filed: January 8, 2013
    Date of Patent: October 30, 2018
    Assignee: ICB INTERNATIONAL, INC.
    Inventors: Ram S. Bhatt, Rishi Bhatt
  • Patent number: 10113001
    Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: October 30, 2018
    Assignee: Xencor, Inc.
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes
  • Patent number: 10106608
    Abstract: An anti-CEACAM1 antibody includes at least one antibody heavy chain (VH) domain having antigen binding sites CDR1H, CDR2H and CDR3H, and at least one antibody light chain (VL) domain having antigen binding sites CDR1L, CDR2L and CDR3L. The antigen binding site CDR2H has a sequence homology of at least 80% to the amino acid sequence WINTYTGEPT (SEQ ID No. 21).
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: October 23, 2018
    Assignee: UNIVERSITAET DUISBURG-ESSEN
    Inventors: Karl Sebastian Lang, Bernhard Singer, Vishal Khairnar, Vikas Duhan, Fan Steven Zhou
  • Patent number: 10106609
    Abstract: Provided is a nanometer antibody for human CD7 molecule and an encoding DNA sequence thereof. The nanometer antibody can be efficiently expressed in Escherichia coli, and can be used for preparing an agent for the detection of CD7 molecule and targeted therapy.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: October 23, 2018
    Assignee: PeronGen BioTherapeutics (Suzhou) Co., Ltd.
    Inventors: Lin Yang, Jinle Tang
  • Patent number: 10093740
    Abstract: The invention relates to a bispecific HER2-targeting agent comprising a.) a first polypeptide ligand that binds to HER2 extracellular domain 1, b.) a second polypeptide ligand that binds to HER2 extracellular domain 4 and c.) a linker covalently attaching said first polypeptide ligand to said second polypeptide ligand.
    Type: Grant
    Filed: October 14, 2013
    Date of Patent: October 9, 2018
    Assignee: Universitat Zurich
    Inventors: Rastislav Tamaskovic, Martin Schwill, Andreas Pluckthun, Christian Jost
  • Patent number: 10093624
    Abstract: Disclosed are isoindoline carboxamide, dihydropyrrolopyridine carboxamide, and dihydropyrrolopyrimidine carboxamide compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are isoindoline carboxamide, dihydropyrrolopyridine carboxamide, and dihydropyrrolopyrimidine carboxamide compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of treating diseases during which ROCK is expressed.
    Type: Grant
    Filed: October 12, 2015
    Date of Patent: October 9, 2018
    Assignee: AbbVie Inc.
    Inventors: Rick F. Clark, Michael L. Curtain, Todd M. Hansen, Howard R. Heyman, Helmut Mack, Michael Michaelides, Marina A. Pliushchev, Omar J. Shah, Bryan K. Sorensen, Ramzi Sweis, Chris Tse, Anil Vasudevan, Kevin R. Woller
  • Patent number: 10093746
    Abstract: The present invention relates to compositions and methods of isolated polynucleotides that encode or polypeptides comprising glypican-3 (GPC3). The invention also includes a chimeric antigen receptor (CAR) wherein the CAR is able to target GPC3. The invention further includes methods of treating a subject or diagnosing and treating diseases, disorders or conditions associated with dysregulated glypican-3.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: October 9, 2018
    Assignees: The Trustees of the University of Pennsylvania, The United States of America as represented by the Department of Veterans Affairs
    Inventor: David Kaplan
  • Patent number: 10087237
    Abstract: Herein is reported a method for producing an antibody preparation comprising the steps of a) applying a buffered solution comprising different isoforms of an antibody to a cation exchange chromatography material, b) applying a first solution with a first conductivity to the cation exchange chromatography material, whereby the antibody isoforms remain bound to the cation exchange chromatography material, and c) applying a second solution with a second conductivity to the cation exchange chromatography material and thereby obtaining the antibody preparation, whereby the conductivity of the second solution exceeds the conductivity of the first solution by not more than 10%.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: October 2, 2018
    Assignee: F. HOFFMANN-LA ROCHE AG
    Inventors: Roberto Falkenstein, Klaus Schwendner, Bernhard Spensberger
  • Patent number: 10087245
    Abstract: The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: October 2, 2018
    Assignees: F. HOFFMANN-LA ROCHE AG, INSTITUT PASTEUR, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
  • Patent number: 10087244
    Abstract: The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: October 2, 2018
    Assignee: ESBATech, an Alcon Biomedical Research Unit LLC
    Inventors: Leonardo Jose Borras, David Urech
  • Patent number: 10081676
    Abstract: Provided are novel IL-32 binding molecules of human origin, particularly human anti-IL-32 antibodies as well as IL-32 binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy are described.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: September 25, 2018
    Assignee: ImmunoQure AG
    Inventors: Adrian Hayday, Kai Kisand, Kai Krohn, Annalisa Macagno, Shimobi Onuoha, Paert Peterson, Mike Rothe, Martin Woodward, Syeda F. Y. Haque
  • Patent number: 10077301
    Abstract: The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-21 (IL-21) and uses thereof, e.g., in therapy.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: September 18, 2018
    Assignee: Monash University
    Inventors: Charles Reay Mackay, Di Yu
  • Patent number: 10077299
    Abstract: The present invention relates to a self-cleaving fusion protein including a target protein, a peptide consisting of amino acid sequence represented by LPXTG, a domain of Sortase A having cleaving function, and a tag, which are sequentially positioned from the amino terminal; a nucleic acid encoding the same; an expression vector including the nucleic acid of the present invention; and a cell transformed with the expression vector of the present invention. In addition, the present invention relates to a method for refining a target protein including culturing, dissolving, and purifying the transformed cell, and a method for preparing a therapeutic antibody-drug conjugate by using the purifying method.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: September 18, 2018
    Assignee: AbTLAS CO., LTD.
    Inventors: Byeong Doo Song, Jee Sun Yun, Hyo Jung Choi, Hye In Kim, Eung-Suk Lee
  • Patent number: 10072085
    Abstract: The present disclosure relates to ?M-14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: September 11, 2018
    Assignee: Kirin-Amgen, Inc.
    Inventors: Dingjiang Liu, Holly Zhuohong Huang, David Andrew Martin, Christopher Boyd Russell, David H. Salinger, Scott Walter Baumgartner, Christopher Endres
  • Patent number: 10072093
    Abstract: A polypeptide which binds to the surface of AML blast cells and is internalized upon binding to the AML blast cells.
    Type: Grant
    Filed: July 4, 2014
    Date of Patent: September 11, 2018
    Assignees: FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V., RHEINISCH-WESTFALISCHE TECHNISCHE HOCHSCHULE AACHEN
    Inventors: Stefan Barth, Jenny Fitting, Mehmet Kemal Tur
  • Patent number: 10066267
    Abstract: The disclosure is directed to novel predictive methods and personalized therapies for treating asthma. Specifically, this disclosure relates to methods of treating a patient having asthma by selectively administering an IL-13 antagonist, on the basis of that patient being genetically predisposed to have a favorable response to treatment with the IL-13 antagonist. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful in predicting the likelihood that a patient having asthma will respond to treatment with an IL-13 antagonist.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: September 4, 2018
    Assignee: Novartis AG
    Inventors: Amy Damask, Steven Lewitzky, Michael Rotte
  • Patent number: 10066018
    Abstract: By means of amino acid sequence alterations, the present inventors succeeded in providing constant regions that can confer antibodies with favorable properties, particularly as pharmaceuticals. The variants of the constant regions provided by the present invention will remarkably reduce heterogeneity when applied to antibody production. That is, homogeneity of antibodies can be maintained at a high level by introducing the alterations provided by the present invention into the antibody heavy chain constant regions. More specifically, decrease in homogeneity caused by —SS— bond linkage differences in the heavy chains of antibody molecules can be prevented. Furthermore, in a preferred embodiment of the present invention, pharmacokinetics of antibodies can be improved and decrease in homogeneity caused by deletion of the C terminus in the antibody constant region can be ameliorated.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: September 4, 2018
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Atsuhiko Maeda, Hirotake Shiraiwa
  • Patent number: 10067133
    Abstract: The present invention provides methods of classifying cluster of differentiation (CD) marker phenotype for hematopoietic cancer cells using multiple circulating cell-free CD markers in bodily fluid. In other aspects, treatment and disease progression of particular hematopoietic cancers can be monitored by measuring the levels of CD and other markers in bodily fluids of a patient.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: September 4, 2018
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Maher Albitar
  • Patent number: 10059952
    Abstract: Method and system for expression systems, based on ade1 and ade2 auxotrophic strains of yeast and fungi, including P. pastoris are disclosed. The expression systems are useful for increased cellular productivity of transformed cell lines and for production of recombinant glycoproteins at industrial scale.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: August 28, 2018
    Assignee: GLYCOFI, INC.
    Inventor: Juergen Nett
  • Patent number: 10059772
    Abstract: The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: August 28, 2018
    Assignee: RINAT NEUROSCIENCE CORP.
    Inventors: Chia-Yang Lin, Li-Fen Lee, Wenwu Zhai
  • Patent number: 10053513
    Abstract: Antibody and other Fc-containing molecules with variations in the Fc region with reduced binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: August 21, 2018
    Assignee: Janssen Biotech, Inc.
    Inventors: Stephen McCarthy, Bernard Scallon, Susan Tam, William Strohl, Omid Vafa
  • Patent number: 10047155
    Abstract: The present invention relates to isolated antibodies and antigen-binding fragments thereof which bind human BMP9 and compositions and methods of use thereof.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: August 14, 2018
    Assignee: NOVARTIS AG
    Inventors: Zijun Chen, Sujun Deng, Yun He, Dagang Huang, Markus Kugler, Qian Li, Chris Xiangyang Lu, Xiao Luo, Yongqiang Shan, Kathrin Ulrike Tissot-Daguette, Jing Wu
  • Patent number: 10047166
    Abstract: A novel humanized anti-IgE antibody is disclosed. The antibody is capable of binding to free IgE, membrane-bound IgE on B lymphocytes, IgE bound by CD23, but not to IgE bound by high-affinity IgE.Fc receptor on mast cells. The present invention relates to the treatment of IgE-mediated diseases, including allergic asthma, allergic rhinitis, atopic dermatitis, food allergy, chronic spontaneous (idiopathic) urticaria, chronic rhinosinusitis, systemic mastocytosis, cutaneous mastocytosis, allergic bronchopulmonary aspergillosis, recurrent idiopathic angioedema, and eosinophil-associated gastrointestinal disorder by administering the anti-IgE antibody of the present invention.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: August 14, 2018
    Inventors: Jiun-Bo Chen, Yu-Yu Shiung, Tse-Wen Chang
  • Patent number: 10047162
    Abstract: Herein is reported a method for reducing the aggregation of an immunoglobulin in solution comprising the steps of i) comparing the amino acid sequence of the fourth framework region of the heavy chain of an antibody with a reference or germline sequence and determining whether one or more threonine residues and/or serine residues have been replaced by a different amino acid residue, and ii) modifying the amino acid sequence of the immunoglobulin by reverting the exchanged threonine residues and/or serine residues back to threonine or serine of the reference or germline sequence and thereby reducing the aggregation of an immunoglobulin in solution.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: August 14, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Hubert Kettenberger, Stefan Klostermann, Ulrich Kohnert, Sebastian Neumann
  • Patent number: 10047121
    Abstract: The present invention relates to amyloid-beta (A?) binding proteins. Antibodies of the invention have high affinity to ??(20-42) globulomer or any ?? form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: August 14, 2018
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Stefan Barghorn, Heinz Hillen, Andreas Striebinger, Simone Giaisi, Ulrich Ebert, Chung-Ming Hsieh
  • Patent number: 10040857
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: August 7, 2018
    Assignee: MEDIMMUNE, LLC
    Inventors: Partha S. Chowdhury, David Tice, Zhan Xiao, Philipp Steiner, Krista Kinneer, Marlon Rebelatto
  • Patent number: 10040769
    Abstract: The invention relates to HDAC inhibitors for use in the treatment of diabetic peripheral neuropathy in a subject in need thereof. Also provided herein are methods for treating diabetic peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: August 7, 2018
    Assignee: REGENACY PHARMACEUTICALS, LLC
    Inventors: Olga Golonzhka, Matthew B. Jarpe
  • Patent number: 10040867
    Abstract: It has been established that cancer cells with oncogenic mutants in the small GTPase K-Ras are susceptible to antibodies that bind intracellular guanosine, but delivery of antibodies into cells can be challenging. A subset of lupus autoantibodies is associated with anti-guanosine activity, and is capable of cellular penetration. These antibodies have potential as therapeutic agents targeted towards K-Ras associated malignancies.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: August 7, 2018
    Assignees: Yale University, The United States of America, as Represented by The Department of Veterans Affairs
    Inventors: James E. Hansen, Richard H. Weisbart, Melissa Young, Philip W. Noble
  • Patent number: 10035859
    Abstract: Humanized antibodies and antibody fragments thereof that bind to ?v?6 are disclosed. Also disclosed are methods of using these antibodies and antibody fragments to treat or prevent ?v?6-mediated diseases such as fibrosis and cancer.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 31, 2018
    Assignee: Biogen MA Inc.
    Inventors: Shelia M. Violette, Paul H. Weinreb, Timothy David Jones, Francis Joseph Carr, Anja Sibylle Tessarz
  • Patent number: 10035860
    Abstract: Humanized antibodies and antibody fragments thereof that bind to ?v?6 are disclosed. Also disclosed are methods of using these antibodies and antibody fragments to diagnose, treat, and/or prevent ?v?6-mediated diseases such as acute tissue injury, fibrosis, and cancer.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 31, 2018
    Assignee: Biogen MA Inc.
    Inventors: Shelia M. Violette, Paul H. Weinreb, Timothy David Jones, Francis Joseph Carr, Anja Sibylle Tessarz
  • Patent number: 10035823
    Abstract: Provided are compositions, including isolated, synthetic or recombinant peptides for: expanding regulatory T cells (Treg) populations; for treating or ameliorating a vascular inflammation, and Kawasaki disease (KD) or a pediatric acute vasculitis of the coronary arteries, including vascular coronary abnormalities, and acute or chronic vascular inflammatory abnormalities, and methods for making and using them.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: July 31, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Alessandra Franco
  • Patent number: 10023638
    Abstract: The current invention provides human variable chain framework regions and humanized antibodies comprising the framework regions, the antibodies being specific for integrin ?1. The invention also provides methods for utilizing the antibodies, for example to treat diseases such as cancer.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: July 17, 2018
    Assignee: Oncosynergy, Inc.
    Inventor: W. Shawn Carbonell
  • Patent number: 10023840
    Abstract: The invention provides an animal model and methods of generating large numbers of diverse, functional, naïve T cells in mice using bone marrow cells from adult donors.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: July 17, 2018
    Assignees: The Trustees of Columbia University in the City of New York, The General Hospital Corporation
    Inventors: Megan Sykes, Hannes Kalscheuer
  • Patent number: 10023636
    Abstract: The present invention provides caninized murine anti-human PD-1 antibodies that have specific sequences and a high binding affinity for canine PD-1. The invention also relates to use of these antibodies in the treatment of dogs.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: July 17, 2018
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey, Leonard G. Presta
  • Patent number: 10016425
    Abstract: Anti-ulcerative colitis compounds include quinazoline derivatives having the following structural formula: wherein R is H, OH, or OCH3, R1 is OH or OCH3, and R2 is OCH3 or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: July 10, 2018
    Assignee: KING SAUD UNIVERSITY
    Inventors: Amani Shafeek Awaad, Ahmed Mahmoud Ahmed Alafify, Reham Mostafa El-Meligy
  • Patent number: 10017577
    Abstract: The invention provides immunoconjugates and methods of using the same.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: July 10, 2018
    Assignee: Genentech, Inc.
    Inventors: Paul Polakis, Peter Dragovich, Thomas Harden Pillow, Shang-Fan Yu
  • Patent number: 10016449
    Abstract: Described herein are pharmaceutical compositions comprising a LMWH preparation having at least one chain having a glycol split uronic acid residue (UG) in the preparation and uses thereof.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: July 10, 2018
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Kelly Neelon, Gary Mills, James Anderson
  • Patent number: 10016434
    Abstract: Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: July 10, 2018
    Assignee: Pharmacyclics LLC
    Inventors: Jun Chen, Joseph J. Buggy, Laurence Elias
  • Patent number: 10017762
    Abstract: The present disclosure provides methods for inhibiting and/or reducing self-reactive IgE and/or basophils, thereby treating or preventing lupus, lupus nephritis, and lupus-related disorders.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: July 10, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Juan Rivera, Nicolas Charles
  • Patent number: 10010611
    Abstract: The invention provides stable aqueous pharmaceutical formulations comprising a therapeutic antibody, trehalose, a buffer, and optional surfactant, and having a pH in the range of about 5.5 to about 7.0. The invention also provides methods for making such formulations and methods of using such formulations.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 3, 2018
    Assignee: GENENTECH, INC.
    Inventors: Yatin Gokarn, Isidro E. Zarraga, Jonathan Zarzar, Thomas Patapoff
  • Patent number: 10010520
    Abstract: The present invention relates to a combined application of isothiocyanate compounds and anti-cancer drugs, in particular to a composition, comprising: (A) a therapeutically effective amount of a first active ingredient, the first active ingredient being an isothiocyanate compound or derivative thereof; (B) a therapeutically effective amount of a second active ingredient, the second active ingredient being anti-cancer drugs effecting or influencing DNA, kinase inhibitor anti-cancer drugs or endocrine therapy hormonal anti-cancer drugs, the mass ratio of the first active ingredient and the second active ingredient being from 1:10000 to 10000:1. Also disclosed are an active ingredient composition, kit, pharmaceutical composition and uses thereof in the preparation of anti-cancer drugs. The composition, active ingredient composition and kit have excellent effect of inhibiting the growth of cancer cells.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: July 3, 2018
    Assignee: JC (Wuxi) Company, Inc.
    Inventors: Jingcai Cheng, Chunxia Zhang, Zhiwei Cheng
  • Patent number: 10011659
    Abstract: Methods of treating a subject having cancer exhibiting a resistance to a tyrosine kinase inhibitor (TKI) are provided. Accordingly, there is provided a method comprising administering to the subject a therapeutically effective amount of antibodies comprising an anti-EGFR antibody, an anti-HER2 antibody and an anti-HER3 antibody. Also provided are compositions and articles of manufacture for treating cancer resistance to a TKI. Also provided are methods of treating non-resistant tumors.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: July 3, 2018
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yosef Yarden, Maicol Mancini, Nadège Gaborit
  • Patent number: 10011648
    Abstract: A human neutralizing monoclonal antibody is directed against the VP1 protein of JC virus. The JC virus is responsible for progressive multifocal leukoencephalopathy (PML). The antibody is used in a therapeutic or prophylactic treatment of a JCV infection or of a disease associated with a JCV infection, such as progressive multifocal leukoencephalopathy (PML). The antibody is also used in the diagnosis of JCV infections or of diseases associated with JCV infections.
    Type: Grant
    Filed: June 26, 2013
    Date of Patent: July 3, 2018
    Assignee: POMONA RICERCA S.r.l.
    Inventors: Roberto Burioni, Massimo Clementi
  • Patent number: 10006080
    Abstract: The present invention relates to medicine, hematology, biotechnology and fundamental biological research; it can be used for diagnostic and research purposes when studying blood coagulation. One of the aspects of the invention is a polypeptide for selective inhibition of contact activation factor XIIa in a sample of blood or plasma, which comprises the sequence of infestin-4 MutB (SEQ ID NO: 1), where this sequence can have modifications outside the area of the inhibitory loop. Another aspect of the invention is a method of studying coagulation in the test sample, which includes bringing the sample into contact with this polypeptide, bringing a coagulation activator into contact with the sample, and measuring the coagulation parameters. Yet another aspect of the invention is a method of blood anticoagulation by this polypeptide for collection purposes and in order to increase the storage time of the sample.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: June 26, 2018
    Assignee: OBSCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYU “GEMATOLOGICHESKAYA KORPORATSIYA”
    Inventors: Vladimir Nikolaevich Kolyadko, Fazoil Inoyatovich Ataullakhanov, Mikhail Aleksandrovich Panteleev, Tatyana Alekseevna Vuymo, Ruzanna Armenovna Ovsepyan, Stepan Sergeevich Surov, Vera Anatoljevna Korneeva
  • Patent number: 10004708
    Abstract: Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: June 26, 2018
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Patent number: 10005843
    Abstract: Anti-TNFRSF25 antibodies and variants thereof, including those that bind to an epitope in the region of amino acids 48-71, are disclosed. Also contemplated are uses of the antibodies in research, diagnostic, and therapeutic applications.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: June 26, 2018
    Assignee: PELICAN THERAPEUTICS, INC.
    Inventors: Taylor H. Schreiber, Jeff T. Hutchins
  • Patent number: 10005847
    Abstract: The present disclosure relates to a novel class of anti-HER2 monoclonal antibodies comprising a homogeneous population of anti-HER2 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-HER2 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: June 26, 2018
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu
  • Patent number: 10000562
    Abstract: Formulations comprising an anti-IL-13 antibody are provided, including pharmaceutical formulations and methods of using such formulations.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: June 19, 2018
    Assignee: GENENTECH, INC.
    Inventors: Ajay Deshmukh, Joumana Zeid, Thomas M. Scherer